Abstract: The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population.

Abstract: The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population.

Abstract: A method for caching targeted webpage content is disclosed. In one embodiment, such a method includes dividing a cacheable content pertaining to a website into a static portion and a dynamic frame for displaying visitor targeted content. The method determines a result for one or more targeting rules applied to a visitor's activity on a portion of the website and provides the result to the visitor's browser. The method further includes loading the dynamic frame of the cacheable content with visitor targeted content based on the provided result. A corresponding apparatus and computer program product are also disclosed.

Abstract: A system for quantum teleportation of a quantum state of an input photon, including: a light emitting diode configured to produce a polarization entangled photon pair; a beam splitter configured to direct photons of the entangled photon pair along respective first and second paths; a measurement unit performing a joint measurement on the input photon; a timing unit configured to measure a first delay between the input photon and the photon of the entangled photon pair at a point of maximum indistinguishability of the photons as they pass through the joint measurement unit, and to measure a second delay between the two photons of the entangled photon pair as they exit the light emitting diode; a controller configured to determine a teleportation measurement is valid if the first delay is within a first predetermined timing window and the second delay is within a second predetermined timing window.

Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

Abstract: The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.

Abstract: In a method of hydraulically fracturing a hydrocarbon-bearing subterranean formation, a proppant stage is introduced into the fracture which contains a gaseous fluid and an ultra lightweight proppant suspended in a viscosified aqueous fluid. The gaseous fluid of the proppant stage contains at least about 90 volume percent of the combination of gaseous fluid and aqueous fluid. A pad fluid may first be introduced into the formation, the pad fluid containing a gaseous fluid and, optionally, an aqueous fluid. The gaseous fluid of the pad fluid mixture typically contains at least 70 volume percent of the mixture.

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.

Abstract: Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonistm are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.

Abstract: In a method of hydraulically fracturing a hydrocarbon-bearing subterranean formation, a proppant stage is introduced into the fracture which contains a gaseous fluid and an ultra lightweight proppant suspended in a viscosified aqueous fluid. The gaseous fluid of the proppant stage contains at least about 90 volume percent of the combination of gaseous fluid and aqueous fluid. A pad fluid may first be introduced into the formation, the pad fluid containing a gaseous fluid and, optionally, an aqueous fluid. The gaseous fluid of the pad fluid mixture typically contains at least 70 volume percent of the mixture.

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying dengue status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with dengue or not infected with dengue. The biomarkers can be detected by SELDI mass spectrometry.

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.

Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

Abstract: This present invention compositions and methods of treating, diagnosing, prognosing cancer and methods of accessing/monitoring the responsiveness of a cancer cell to a therapeutic compound.

Abstract: In a method of hydraulically fracturing a hydrocarbon-bearing subterranean formation, a proppant stage is introduced into the fracture which contains a gaseous fluid and an ultra lightweight proppant suspended in a viscosified aqueous fluid. The gaseous fluid of the proppant stage contains at least about 90 volume percent of the combination of gaseous fluid and aqueous fluid. A pad fluid may first be introduced into the formation, the pad fluid containing a gaseous fluid and, optionally, an aqueous fluid. The gaseous fluid of the pad fluid mixture typically contains at least 70 volume percent of the mixture.

Abstract: Provided are methods and kits for detecting amplification of a target nucleic acid during a real time quantitative polymerase chain reaction process using a universal detection system. The detection system uses an unlabeled probe that detects the amplified target nucleic acid and interacts with a universal detection module.

Abstract: A photon source comprising a semiconductor heterostructure, said semiconductor heterostructure comprising a quantum well, a barrier region adjacent said quantum well and a quantum dot provided in said quantum well, the photon source further comprising electrical contacts and a power supply coupled to first and second electrical contacts configured to apply a tuneable electric field across said quantum dot to control the emission energy of said quantum dot, said electric field being tuneable across an operating range an wherein the tunnelling time of carriers from said quantum dot to said first electrical contact and the tunnelling time of carriers from said quantum dot to said second electrical contact are greater than the radiative decay time of an exciton in said quantum dot over said operating range for controlling the emission energy, said photon source being configured such that emission from a single quantum dot exits said photon source.

Abstract: In a method of hydraulically fracturing a hydrocarbon-bearing subterranean formation, a proppant stage is introduced into the fracture which contains a gaseous fluid and an ultra lightweight proppant suspended in a viscosified aqueous fluid. The gaseous fluid of the proppant stage contains at least about 90 volume percent of the combination of gaseous fluid and aqueous fluid. A pad fluid may first be introduced into the formation, the pad fluid containing a gaseous fluid and, optionally, an aqueous fluid. The gaseous fluid of the pad fluid mixture typically contains at least 70 volume percent of the mixture.

Abstract: In a method of hydraulically fracturing a hydrocarbon-bearing subterranean formation, a proppant stage is introduced into the fracture which contains a gaseous fluid and an ultra lightweight proppant suspended in a viscosified aqueous fluid. The gaseous fluid of the proppant stage contains at least about 90 volume percent of the combination of gaseous fluid and aqueous fluid. A pad fluid may first be introduced into the formation, the pad fluid containing a gaseous fluid and, optionally, an aqueous fluid. The gaseous fluid of the pad fluid mixture typically contains at least 70 volume percent of the mixture.

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying babesia status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with babesia or not infected with babesia. The biomarkers can be detected by SELDI mass spectrometry.